Source:http://linkedlifedata.com/resource/pubmed/id/11972982
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
2002-4-25
|
pubmed:abstractText |
We conducted a national molecular epidemiologic survey of HIV-1 strains in Nigeria to determine the most prevalent subtype(s) for use in developing candidate vaccines. A total of 230 HIV-1-positive blood samples collected from 34 of the 36 Nigerian states were analyzed by our modified env gp41-based heteroduplex mobility assay (HMA) and/or gp41 sequencing and analysis. Overall, 103 (44.8%) were subtype A, 125 (54.3%) were subtype G, one (0.4%) was subtype C, and one (0.4%) was subtype J, and one (0.4%) was unclassifiable. To further characterize Nigerian viruses to aid in strain selection for candidate vaccines, one gp41 subtype G and five gp41 subtype A strains were selected for full envelope sequencing. The one subtype G sequence had consistent phylogenies throughout gp160, using programs to detect recombination. However, all five sequences that were primarily subtype A in gp41 were found to be recombinant viruses. Two of the five (40%) were A/G/J mosaics with common breakpoints. The remaining three gp160 recombinants all had their own unique break points: two A/? and one A/?/G, however, all five had the majority of their mosaic breakpoints occurring in gp41. None of the five were consistent with the circulating recombinant form (CRF)02_AG strain previously reported to be prevalent in West Africa. In conclusion, we showed a clear dominance and widespread distribution of gp41 subtypes A and G in fairly equal proportions, suggesting that vaccines designed for use in this geographic locale should incorporate the gene(s) of both subtypes. However, appreciating the magnitude of diversity of HIV-1 strains in Nigeria may require sequencing and analysis of longer gene regions for the identification of prevalent or emerging CRFs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0264-410X
|
pubmed:author |
pubmed-author:AgwaleS MSM,
pubmed-author:EdubioAA,
pubmed-author:GasJJ,
pubmed-author:GbounM SMS,
pubmed-author:HoncFF,
pubmed-author:KalishM LML,
pubmed-author:NjokuMM,
pubmed-author:OdamaLL,
pubmed-author:PieniazekDD,
pubmed-author:ReitzMM,
pubmed-author:RobbinsK EKE,
pubmed-author:SaekhouAA,
pubmed-author:Sani-GwarzoNN,
pubmed-author:WambebeCC,
pubmed-author:ZeeDD
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2131-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11972982-AIDS Vaccines,
pubmed-meshheading:11972982-Amino Acid Sequence,
pubmed-meshheading:11972982-Clinical Trials as Topic,
pubmed-meshheading:11972982-HIV Envelope Protein gp160,
pubmed-meshheading:11972982-HIV Envelope Protein gp41,
pubmed-meshheading:11972982-HIV-1,
pubmed-meshheading:11972982-Humans,
pubmed-meshheading:11972982-Nigeria,
pubmed-meshheading:11972982-Phylogeny,
pubmed-meshheading:11972982-Recombination, Genetic
|
pubmed:year |
2002
|
pubmed:articleTitle |
Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.
|
pubmed:affiliation |
Division of Vaccine Research, Institute of Human Virology, Baltimore, MD, USA.
|
pubmed:publicationType |
Journal Article
|